Form 4: Merus Director Pucci's Options Cancelled in Tender Offer
Statement of Changes in Beneficial Ownership
Merus N.V. Director Paolo Pucci's stock options were cancelled and cashed out following Genmab's tender offer for Merus shares at $97.00 per share.
Summary
- Merus N.V. Director Paolo Pucci reported the cancellation of all his outstanding share options.
- This cancellation occurred on December 12, 2025, as a result of a tender offer by Genmab A/S and its subsidiary, Genmab Holding II B.V., for Merus N.V. common shares.
- The tender offer consideration was $97.00 per share.
- Pucci received a cash payment for each option, calculated as the difference between the $97.00 offer consideration and the option's exercise price, multiplied by the number of shares underlying the option.
- The options had various exercise prices ranging from $16.09 to $48.73.
- Following these transactions, Pucci beneficially owns 0 derivative securities.
Sentiment
Score: 8
Explanation: The reporting person successfully monetized their stock options at a significant premium over their exercise prices due to the tender offer, indicating a favorable financial outcome for them.
Positives
- Director Paolo Pucci received a cash payout for his stock options, realizing value from his holdings.
- The tender offer price of $97.00 per share was significantly higher than all reported option exercise prices, ensuring a positive return for the option holder.
Future Outlook
The filing reports a completed transaction related to a tender offer, and does not provide forward-looking statements or guidance for Merus N.V. as an ongoing entity, given the acquisition context.
Industry Context
This transaction reflects a consolidation event within the biotechnology or pharmaceutical sector, where larger entities like Genmab acquire companies like Merus N.V. to expand pipelines or market share. Such tender offers are common mechanisms for M&A activity in the industry.
Stakeholder Impact
- Shareholders who tendered their shares received $97.00 per share in cash.
- Option Holders (like Pucci) realized cash value from their options at a premium.
- Merus N.V. as an entity is being acquired, leading to significant changes in its ownership and operational structure.
Next Steps
- The filing indicates the tender offer has been accepted and payment will be made as soon as practicable, implying the completion of the acquisition process for the tendered shares and option payouts.
Key Dates
| Date | Description |
|---|---|
| 2025-09-29 | Merus N.V. entered into a transaction agreement with Genmab A/S and Genmab Holding II B.V. |
| 2025-12-12 | Acceptance Time of the tender offer; Purchaser accepted tendered shares and Paolo Pucci's share options were cancelled. |
| 2030-06-30 | Expiration date of a share option with an exercise price of $16.09 (prior to cancellation). |
| 2031-05-28 | Expiration date of a share option with an exercise price of $21.15 (prior to cancellation). |
| 2032-05-31 | Expiration date of a share option with an exercise price of $18.56 (prior to cancellation). |
| 2033-06-08 | Expiration date of a share option with an exercise price of $23.29 (prior to cancellation). |
| 2034-05-07 | Expiration date of a share option with an exercise price of $48.73 (prior to cancellation). |
| 2035-05-22 | Expiration date of a share option with an exercise price of $41.60 (prior to cancellation). |
Keywords
Merus N.V., MRUS, Genmab, Tender Offer, Stock Options, Beneficial Ownership, SEC Form 4, Paolo Pucci, Acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.